Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: A real-life 52-week retrospective study.
anti-IL-23
guselkumab
psoriasis
real life
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
18
11
2020
revised:
29
11
2020
accepted:
10
12
2020
pubmed:
15
12
2020
medline:
25
5
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
Recent major research advancements have significantly expanded our understanding of psoriasis pathophysiology, resulting in the development of highly effective, targeted therapies. Guselkumab is the first interleukin (IL)-23 inhibitor approved for the treatment of moderate-to-severe-psoriasis, providing a new therapeutical option for psoriasis. The aim of our study was to evaluate the efficacy of guselkumab in psoriatic patients who previously failed anti-IL-12/23 and/or anti-IL-17 treatment. A 52-week single-center retrospective study was performed enrolling moderate-to-severe patients attending our Psoriasis Care Center from October 2018 to May 2020. Study population included 13 patients; 46.1% have been previously treated with ustekinumab, while 69.2% have previously failed an anti-IL-17 treatment (38.5% secukinumab, 30.8% ixekizumab, and 38.5% both). At baseline, mean Psoriasis Area and Severity Index was 13.2 ± 6.8, reducing up to 0.5 ± 0.7 at week 52 (P < .001). Body surface area reduced from 22.3 ± 10.5 (baseline) to 0.8 ± 1.1 at week 52 (P < .001). No statistically significant differences have been found between patients previously treated with anti-IL-12/23 compared to anti-IL-17 or both. Only one patient discontinued guselkumab at week 36 due to secondary inefficacy. This is a single institution study with a relatively small sample size. Our real-life data confirm trial results, showing guselkumab as a safe and effective option in patients with moderate-to-severe psoriasis even in those who previously failed ustekinumab and/or anti-IL-17 treatment.
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
guselkumab
089658A12D
Ustekinumab
FU77B4U5Z0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14673Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Chen L, Deshpande M, Grisotto M, et al. Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice. Sci Rep. 2020;10(1):8259.
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis [published correction appears in N Engl J Med. 2017;376(21):2097]. N Engl J Med. 2017;376(10):957-970.
Megna M, Balato A, Napolitano M, et al. Psoriatic disease treatment nowadays: unmet needs among the "jungle of biologic drugs and small molecules". Clin Rheumatol. 2018;37(7):1739-1741.
Markham A. Guselkumab: first global approval. Drugs. 2017;77(13):1487-1492.
Ibler E, Gordon KB. IL-23 inhibitors for moderate-to-severe psoriasis. Semin Cutan Med Surg. 2018;37(3):158-162.
Megna M, Ruggiero A, Camela E, Fabbrocini G, Marasca C. A case of erythrodermic psoriasis successfully treated with guselkumab. Dermatol Ther. 2020;XXX:e13238 [Epub ahead of print].
Megna M, Fabbrocini G, Cinelli E, Camela E, Ruggiero A. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. J Dermatolog Treat. 2020;1-5 [Epub ahead of print]. https://doi.org/10.1080/09546634.2020.1800577.
Megna M, Balato A, Raimondo A, Balato N. Guselkumab for the treatment of psoriasis. Expert Opin Biol Ther. 2018;18(4):459-468.
Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114-123.
Allen SJ, Lumb KJ. Protein-protein interactions: a structural view of inhibition strategies and the IL-23/IL-17 axis. Adv Protein Chem Struct Biol. 2020;121:253-303.
Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(10):1616-1626.
Chiu HY, Chu TW, Cheng YP, Tsai TF. The association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab. PLoS One. 2015;10(11):e0142930.
Rodriguez Fernandez-Freire L, Galán-Gutierrez M, Armario-Hita JC, Perez-Gil A, Ruiz-Villaverde R. Guselkumab: short-term effectiveness and safety in real clinical practice. Dermatol Ther. 2020;XXX:e13344 [Epub ahead of print].
Fougerousse AC, Ghislain PD, Reguiai Z, et al. Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study. J Eur Acad Dermatol Venereol. 2020;34(10):e644-e646. https://doi.org/10.1111/jdv.16511.
Casseres RG, Rosmarin D. Two cases of worsening psoriasis after switching from ustekinumab to guselkumab. J Psoriasis Psoriatic Arthritis. 2019;4(3):153-154. https://doi.org/10.1177/2475530319835792.
Maliyar K, O'Toole A, Gooderham MJ. Long-term single center experience in treating plaque psoriasis with guselkumab. J Cutan Med Surg. 2020;24(6):588-595. https://doi.org/10.1177/1203475420932514.
Macaluso FS, Orlando A, Cottone M. Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. Expert Opin Biol Ther. 2019;19(2):89-98.
Snast I, Sherman S, Holzman R, Hodak E, Pavlovsky L. Real-life experience of guselkumab in patients with psoriasis. Dermatol Ther. 2020;XXX:e13964. https://doi.org/10.1111/dth.13964. [Epub ahead of print].
Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020;9(7):2170. https://doi.org/10.3390/jcm9072170.
Benhadou F, Ghislain PD, Guiot F, et al. Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16715.